JSE-listed pharmaceutical group Adcock Ingram Holdings expects to report a 24% to 25% year-on-year increase in earnings per share (EPS) to between 492c and 495c for the financial year ended June 30.
This compares with EPS of 396c posted in the prior financial year.
Headline earnings per share (HEPS) are expected to increase by 24% year-on-year to between 500c and 502c, compared with HEPS of 404.7c reported in the prior year.
The company attributes its improved performance to better trading conditions than the prior Covid-19-stricken year, as well as improved demand in over-the-counter and consumer healthcare products.
Adcock will release its results for the 2022 financial year on or about August 25.